The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy  by Clark, Peter E.
The role of VHL in clear-cell renal cell carcinoma and
its relation to targeted therapy
Peter E. Clark1
1Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
The basic biology underlying the development of clear-cell
renal cell carcinoma (ccRCC) is critically dependent on the
von Hippel–Lindau gene (VHL), whose protein product is
important in the cell’s normal response to hypoxia.
Aberrations in VHL’s function, either through mutation or
promoter hypermethylation, lead to accumulation of the
transcriptional regulatory molecule, hypoxia-inducible factor
alpha (HIFa). HIFa can then dimerize with HIFb and
translocate to the nucleus, where it will transcriptionally
upregulate a series of hypoxia-responsive genes, including
vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), and others. Binding of these ligands to
their cognate receptors activates a series of kinase–
dependent signaling pathways, including the RAF–MEK–ERK
and phosphatidylinositol-3 kinase–AKT–mTOR pathways.
Targeted agents developed and now approved for use in
advanced ccRCC include humanized monoclonal antibodies
against VEGF, small-molecule tyrosine kinase inhibitors, and
inhibitors of mTOR. Understanding the biology of ccRCC is
critical in understanding the current therapy for the disease
and in developing novel therapeutics in the future. This
review will provide an overview of the genetics of ccRCC,
with an emphasis on how this has informed the development
of the targeted therapeutics for this disease.
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There were an estimated 54,390 newly diagnosed cases of
kidney cancer in 2008 and over 13,000 deaths.1 For many
patients, the disease is localized when it is found, and for
them, surgical excision remains the standard of care and
offers excellent long-term recurrence-free survival. However,
for those patients who either present with metastatic disease
or develop distant relapse after their surgery, the scenario is
far less sanguine. Renal-cell carcinoma (RCC) is notoriously
resistant to traditional cytotoxic chemotherapy, and for
several decades the mainstay of therapy was based on
immunotherapy, typically through either high-dose inter-
leukin-2 (IL-2) or interferon alpha (IFNa). Neither of these
approaches was particularly satisfactory. High-dose IL-2 can,
rarely, produce long-term complete remission, but this is
generally seen in considerably less than 5% of the time and
the overall response rates are on the order of 20%.2 This rate
also comes at the cost of very substantial toxicity. Although
IFNa is less toxic than high-dose IL-2, it is arguably less
effective in that the overall response rates are generally lower,
and it almost never results in long-term remission. The way
forward in treating RCC, at least the most common clear-cell
histological variant, had to await a better understanding of
the biology of RCC and the subsequent development of the
so-called targeted therapies to attack the components of that
biology. The purpose of this review will be to provide an
overview of the genetics of clear-cell RCC (ccRCC), and in
particular, the central role played by the von Hippel–Lindau
gene (VHL). It will also link those principles to the targeted
therapies, which have become central to the contemporary
management of ccRCC. This story represents a satisfying
example of how basic science and molecular biology (the
bench) has moved into the clinical setting (the bedside), a
theme that will likely be repeated across a range of other
diseases over the next decade.
VHL AND ccRCC
Understanding the biology of ccRCC starts with the discovery
and characterization of the VHL gene. VHL disease is an
inherited neoplasia syndrome, whose hallmark is the
development of benign and malignant tumors across several
organ systems.3,4 Its incidence is one in 36,000 births, and is
inherited as an autosomal dominant trait with over 90%
penetrance by the age 65 years in affected individuals.5–7 The
characteristic tumors include hemangioblastomas of the
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central nervous system, retinal hemangioblastomas, pheo-
chromocytomas, and renal neoplasms, including renal cysts
and ccRCC.3 ccRCC, in particular, has a profound influence
on families with the disease, as the leading cause of death in
this group is metastatic ccRCC.7
The VHL gene’s discovery grew at first from the
observation that the ccRCC in VHL disease was identical to
the sporadic, nonfamilial form in every respect, except that it
tended to be multifocal and occured at a younger age. These
characteristics fit the profile of a familial tumor syndrome
that was secondary to the loss/mutation of a tumor
suppressor gene. Earlier studies looking at different kindreds
with a familial tendency toward developing sporadic ccRCC
had consistently shown aberrations of the short arm of
chromosome 3 (3p).8–10 Subsequent studies of both ccRCC
tumors and cell lines confirmed abnormalities of chromo-
some 3p as a unifying theme.11–15 These alterations in
chromosome 3p were not present in the corresponding
normal tissues and were not present in other histological
variants, such as papillary RCC.16,17
Putting together these observations in sporadic ccRCC’s,
with the same tumor type being present in VHL disease,
suggested that the abnormality on chromosome 3p fit the
profile of a tumor suppressor gene. A series of elegant and
ground breaking studies of multiple different kindreds with
VHL disease localized the VHL gene to a relatively small
region on chromosome 3p,18–20 followed in 1993 by the
identification of the VHL gene in a seminal article by Latif
et al.21 Studies since then have shown aberrations of VHL in
the majority of sporadic ccRCCs.22–28 Roughly, half the VHL
mutations found in sporadic clear RCC are frameshift
mutations, whereas the second most common is a missense
mutation.22 Even in cases in which genetic mutations of VHL
have not been identified, other aberrations affecting its
function were noted, such as abnormal promoter hyper-
methylation of VHL, leading to low or absent protein levels.29
For a more in-depth analysis of specific VHL mutations and
their potential relationship to disease biology, the interested
reader is referred to two other previously published in-depth
reviews.30,31
VHL, HIFa, AND HYPOXIA
Normally, VHL’s predominant function is to regulate the
cell’s response to oxygen availability in the local microenvir-
onment.32–37 VHL exists in the cell cytoplasm in complex
with a series of other proteins, specifically elongin B, elongin
C, cullin2, and Rbx, as part of an E3 ligase complex.38–44 This
complex can ubiquitinate proteins and thereby mark them
for subsequent degradation by the cell’s proteasomal
machinery.45,46 In the presence of normal local oxygen levels,
a regulatory molecule, termed hypoxia-inducible factor alpha
(HIFa), is hydroxylated by a series of prolyl hydroxylases. The
presence of a hydroxyl group at these proline residues permits
HIFa to bind to the E3 ligase enzyme complex, mediated
predominantly by VHL protein (see Figure 1).47,48 The
binding of HIFa to VHL and to the E3 ligase complex causes
HIFa to be ubiquitinated and marked for degradation by the
cell’s proteosomal complex.49–54 Therefore, in the normal
circumstance with normal local oxygen availability, HIFa
levels are kept low in the cell. In contrast, during hypoxia,
HIFa is not hydroxylated, and hence does not bind to VHL
protein, and consequently is not degraded. Therefore, as a
normal physiological response to hypoxia, HIFa levels rise in
the cell, allowing it to bind with a similar molecule that is
constitutively present, namely, HIFb (see Figure 1). The
HIFa/b heterocomplex can then translocate to the nucleus
and bind to specific hypoxia response elements in the
promoters of genes that are important in the cell’s response
to hypoxia. Binding of the regulatory HIFa/b complex to the
hypoxia response elements in the promoter of these hypoxia
responsive genes in turn transcriptionally upregulates their
mRNA and subsequent protein levels. The critical genes
upregulated by HIFa include vascular endothelial growth
factor (VEGF), platelet-derived growth factor (PDGF),
transforming growth factor alpha (TGFa), carbonic anhy-
drase IX (CA-IX), erythropoietin, glucose transporter 1
(GLUT-1), and others.
When VHL protein either cannot function because of a
mutation or is abnormally low/absent in the cell (for
example, because of promoter hypermethylation), then
irrespective of the oxygen levels in the cell, HIFa cannot be
bound to the E3 ligase, cannot be degraded, and hence is
constitutively present at a higher level in the cell (see
Figure 1). High levels of HIFa in turn mean that the HIFa/b
complex will interact with the hypoxia response elements in
the nucleus and the genes normally regulated by HIF, such as
VEGF, PDGF, and TGFa, will be abnormally high and lead to
the development of ccRCC.
VASCULAR ENDOTHELIAL GROWTH FACTOR
Of the many proteins upregulated by HIFa, perhaps the one,
which has generated the most interest, is VEGF. This is
because VEGF has a central role in angiogenesis, and it is now
well recognized that this is critical to malignant tumor
progression across a variety of tumors and there is the clinical
observation that ccRCC’s are generally hypervascular tu-
mors.55–57 The VEGF protein family includes several
subtypes, including VEGF-A, -B, -C, -D, -E, and placenta
growth factor-1.58–61 These proteins can bind to one or more
of at least three VEGF receptors (VEGFRs) at the cell surface,
namely, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and
VEGFR-3 (Flt-4).58–61 Of the three, VEGFR-1 and -2 are
thought to be more important for angiogenesis, whereas
VEGFR-3 is thought to be more important for lymphangio-
genesis.61
All three members of the VEGFR family are cell-surface
membrane-associated tyrosine kinases. Binding of the ligand
(VEGF) induces a conformational change in the receptor
allowing specific tyrosine amino acid residues in the protein
to be phosphorylated. This phosphorylation in turn leads to a
downstream cascade of signaling events (see Figure 2). There
are at least two main pathways that these cascades follow.
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One is through the RAF–MEK–ERK series of kinases and the
other is through the phosphatidylinositol-3 kinase (PI3K)–
protein kinase B (AKT)– mammalian target of rapamycin
(mTOR) pathway. It is the activation of these and other
pathways that in turn leads to endothelial cell activation,
proliferation, migration, and cell survival.58–62 The complex
interplay of these events, probably along with similar events
from the other HIF target genes, ultimately leads to
carcinogenesis through a process that has not yet been fully
explained in all its complexity.
A key therapeutic point for the RAF–MEK–ERK and the
PI3K–AKT–mTOR pathways is that both also involve kinases
to regulate their activity. Another important observation
relates to the mTOR, which is downstream of VEGF, but also
acts to increase the starting cellular levels of HIFa.63 In
principle, then, the abnormal VHL function can set up a
vicious positive feedback loop in which HIFa levels rise,
leading to abnormally high levels of VEGF, which binds to
VEGFR resulting in activation of the phosphatidylinositol-3
kinase–AKT pathway to activate mTOR. This can in turn lead
to even higher levels of HIFa. In principle, this could lead to a
vicious positive feedback loop exacerbating the defect started
by abnormal VHL function.
VHL–HIF–VEGF BIOLOGY AND TARGETED THERAPY
The fundamental biology underlying the VHL–HIF–VEGF
cascade described above is important as it is the members of
this biological cascade that form the therapeutic targets for
managing advanced ccRCC. By targeting the components of
the pathway, the process of carcinogenesis and tumor
progression should be reversible. This concept underlies the
so-called ‘targeted therapies’, which have now become the
standard of care for advanced ccRCC.
TARGETING THE VEGF PATHWAY
The most direct way, conceptually, to block the elevated
VEGF in ccRCC would be to inhibit the molecule itself (see
Figure 2). Although several such approaches have been
explored, the best studied so far has been that of the
humanized monoclonal antibody to VEGF, namely, Bevaci-
zumab (Avastin, Genentech, San Francisco, CA, USA).64 This
novel, targeted agent was tested for use in ccRCC in a
randomized phase II trial and was found to lengthen the time
to progression of advanced RCC when compared with
placebo.64 Subsequently, it was tested in a large-scale phase
III trial in combination with IFNa for men with previously
untreated advanced RCC.65 The progression-free survival
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Figure 1 |VHL and HIFa. In the presence of normal tissue oxygenation levels (depicted to the left in figure), prolyl hydroxylases hydroxylate
HIFa. Once hydroxylated, an E3 ligase complex binds HIFa in a process that is VHL dependent. This leads to ubiquitination (Ub) of
HIFa, marking it for degradation by the proteasomal machinery of the cell. In the right of the figure is depicted the disruption of this normal
regulatory process when VHL function is aberrant. In the absence of functional VHL, the E3 ligase complex cannot bind HIFa, irrespective
of its hydroxylation status. This leads to accumulation of HIFa in the cell cytoplasm, allowing it to dimerize with the constitutively present
HIFb, translocate to the nucleus, bind to hypoxia response elements, and regulate gene transcription. HIFa, hypoxia-inducible factor alpha;
HIFb, hypoxia-inducible factor beta; HRE, hypoxia response element; Ub, ubiquitin; VHL, von Hippel–Lindau.
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(PFS) in the combination regimen was 10.2 months,
significantly longer than the 5.4 months in the IFN-alone
arm. On the basis of these studies, Bevacizumab in
combination with IFNa is one of several targeted agents
routinely used in advanced RCC.
An alternate to directly blocking VEGF is to target
downstream signaling from the VEGFR (see Figure 2). As
discussed previously, the VEGFR (as well as PDGF and
TNFa) are tyrosine kinases. Downstream of these tyrosine
kinase receptors are at least two pathways, the RAF–ME-
K–ERK and the PI3K–AKT–mTOR pathways, many of whose
members also rely on tyrosine kinase activity. Targeting the
tyrosine kinases is, therefore, a logical next step in developing
novel therapeutics for ccRCC. The earliest attempts at
developing these tyrosine kinase inhibitors (TKIs) were
relatively specific for the VEGFR itself.66,67 As the results
were generally disappointing, these agents have largely been
abandoned. What became apparent over the course of those
studies was that less specific TKIs that could affect several
different signaling molecules simultaneously were more
effective. Presumably this is because of their ability to
interrupt multiple signaling cascades simultaneously at
multiple different levels using one agent. This conceptual
framework has lead to the development, and now approval,
of several agents in this drug class. There is a seemingly
endless and rapidly expanding pool of potentially active
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Figure 2 |Hypoxia responsive genes. Binding of the HIFa–HIFb heterodimer to the HRE in the promoter region results in transcriptional
upregulation of genes important to the cell’s response to hypoxia. These include vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), transforming growth factor alpha (TGFa), carbonic anhydrase IX (CA-IX), erythropoietin (EPO), glucose
transporter 1 (GLUT-1), and BCL2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3). Binding of ligands, such as VEGF, to their respective
cell surface receptors, such as VEGFR, leads to tyrosine phosphorylation of the receptor and subsequent downstream signaling through
several kinase-dependent pathways, such as the PI3K–Akt–mTOR pathway and the RAS–RAF–MEK–ERK pathway. Note that mTOR leads to
upregulation of basal levels of HIFa. Also shown within these pathways is a subset of the known therapeutic target sites for the monoclonal
antibody to VEGF (bevacizumab), the tyrosine kinase inhibitors (sorafenib and sunitinib), and the mTOR inhibitors (temsirolimus and
everolimus). AKT, protein kinase B; HIFa, hypoxia-inducible factor alpha; HIFb, hypoxia-inducible factor beta; HRE, hypoxia response
element; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol-3 kinase.
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drugs of this type (for example, AG-013736, GW572016,
PTK787/ZK222584, plus others), but for this review, we will
focus on the two such drugs with large-scale, published level I
data confirming their clinical utility and which are now both
approved for use in metastatic RCC. (For a more in-depth
review of the other agents see Lane et al.62; Shaheen and
Bukowski68 and Amato69.)
Sunitinib is an orally bioavailable multitargeted TKI. Pre-
clinical studies have shown that it can block downstream
signaling from several receptors important in ccRCC,
including the receptors for VEGF and PDGF.70,71 Promising
phase I studies in the setting of advanced RCC72 led to the
initiation of two phase II studies in patients who had failed
earlier systemic cytokine therapy (second-line setting). In
these two trials, the partial response rates were 34–40% and
the median time to progression was 8.3–8.7 months.73,74 Both
these data represented substantial improvements over
historical controls, and hence, a large-scale, international,
multicenter, prospective, randomized, phase III trial was
initiated and completed that enrolled 750 patients with
ccRCC, who had not received earlier systemic therapy (front-
line setting).75 The randomization was between sunitinib and
IFNa, and the primary end point of the trial was PFS. The
partial response rate for sunitinib (31%) was significantly
better than that for IFNa (6%). The median PFS was also
significantly better in patients’ who received sunitinib
(11 months) compared with those in the IFNa arm
(5 months). Overall toxicity was manageable. The clear
superiority of the oral TKI sunitinib over IFNa has now led
to its approval for use in the front-line setting for the
treatment of advanced RCC.
Another orally bioavailable multitargeted TKI is sorafenib.
This was originally developed as an inhibitor of Raf-1,
another member of the RAF/MEK/ERK pathway downstream
of such critical receptors as VEGFR and PDGFR.76 Sub-
sequent studies showed that it was also able to block
downstream signaling from a variety of other tyrosine
kinases, including VEGFR, PDGFR, as well as others. As
with sunitinib, the initial phase II studies with sorafenib
showed substantial improvements in PFS, although the
partial response rates were overall much lower.47,77 These
phase II studies led to a large-scale, multicenter, interna-
tional, randomized, prospective trial of 903 patients with
ccRCC who had failed at least one earlier systemic therapy
(second-line therapy).78 The randomization was between
oral sorafenib and placebo. PFS was significantly better in
the sorafenib arm compared with that in placebo, and it
was generally well tolerated, although there were rare
cases of significant hypertension and cardiac ischemia. As a
consequence, sorafenib is also approved for use in
advanced ccRCC, although it is generally used in a second-
line setting.
BLOCKING mTOR
As the aberrations in VHL that underlie the process of
carcinogenesis in ccRCC seem to act predominantly through
the accumulation of HIFa in the cell, another potential way
to target ccRCC is to target HIFa’s starting levels. Although
there are several important pathways that coordinate to
control HIFa expression, the most important from a
therapeutic standpoint is the Akt/mTOR pathway. Activation
of mTOR leads to increased expression of HIFa mRNA and
increased protein expression. In ccRCC, elevation of HIFa
leads to increased signaling along the Akt–mTOR pathway,
which can then lead to transcriptional upregulation of HIFa.
The elevated HIF cannot be targeted for degradation owing
to aberrations in VHL function. This vicious positive
feedback loop, as discussed previously, is thought to be
important in ccRCC and, therefore, a number of agents have
been developed as inhibitors of mTOR. To date, a number of
these compounds have been shown to decrease HIFa levels,
including rapamycin, temsirolimus, and everolimus. (See also
Cho et al.63; Boulay et al.79; Reddy et al.80.) Of these, the two
that now have level I evidence supporting their use in the
setting of ccRCC are temsirolimus and everolimus.
Temsirolimus (derived as a water-soluble ester of siroli-
mus) is able to inhibit mTOR’s kinase activity and lead to cell
cycle arrest. Several phase II trials showed its efficacy, both as
a single agent and in combination with IFNa, in cytokine-
refractory advanced RCC in improving PFS when compared
with historical controls.81,82 A large-scale, prospective,
randomized, phase III trial was completed of patients with
high-risk metastatic RCC (based on the Motzer criteria)
randomized to receive temsirolimus alone, IFNa alone, or
both agents.83 Temsirolimus as monotherapy improved both
PFS and overall survival compared with either IFNa or
combination therapies. Overall, the toxicity noted in the
temsirolimus monotherapy arm was manageable. As a result
of this study, temsirolimus is also an approved agent for use
in advanced RCC and is generally the preferred front-line
option in patients with high-risk metastatic ccRCC.
More recently everolimus, another mTOR inhibitor, was
also tested in a large-scale, prospective randomized placebo-
controlled phase III trial, specifically in patients who had
failed earlier targeted therapies, such as the TKI’s described
previously.84 The patients in the everolimus arm had better
PFS when compared with patients in the placebo arm. It is
anticipated that this will also be approved for use in advanced
ccRCC and is likely to be used in the second-line setting given
the way the randomized trial showing its efficacy was
structured.
CONCLUSION
The biology of ccRCC is a gratifying example of how
discoveries at the bench have directly informed significant
advances at the bedside. The broad principles of this biology
are reasonably well established, including the pathway from
aberrations in VHL, to dysregulated HIFa, downstream
changes in hypoxia responsive genes, such as VEGF, PDGF,
CA-IX, and others, and then further downstream signaling
events through pathways, including RAF–MEK–ERK and
PI3K–AKT–mTOR. Clinically, there is ongoing work to target
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other aspects of this cascade of events. At the more basic
biological level, there are innumerable questions still to be
answered. Examples include: Which of the many hypoxia
responsive genes are the most critical for oncogenesis? What
other, as yet understudied, genes are also involved? How do
the downstream signaling cascades interact, and why do the
normal feedback regulatory mechanisms in the cell fail to
stop these cascades of events? Why are these events more
critical for cancer in the kidney and not in another organ
system such as the lung or bowel? Over time, the answers to
some of these questions will hopefully open up even more
therapeutic avenues for advanced RCC.
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